You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Verona Pharma’s ensifentrine heads for phase 3 chronic obstructive pulmonary disease trial

Verona has announced that it has completed patient enrolment – with more than 800 subjects involved – for its randomised ENHANCE-1 trial.